A new study conducted at Tel Aviv University and the Sheba Medical Center reveals how melanoma cancer cells affect their close environment to support their needs – by forming new lymph vessels in the dermis to go deeper into the skin and spread through the body. The
2023
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: a real-world population-based cohort study of resource utilization
Background — The efficacy-effectiveness gap between randomized trial and real-world evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has been well characterized by previous literature, consistent with initial concerns raised by health technology assessment agencies (HTAs).
Pembrolizumab Plus mRNA Vaccine Leads to Improved RFS in High-Risk Melanoma
In the adjuvant setting for high-risk melanoma, findings from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial (NCT03897881) that evaluated mRNA-4157/V940 in combination with pembrolizumab (Keytruda) showed improved recurrence-free survival (RFS) compared with pembrolizumab alone.
Melanoma treatment delays increased in Asian American, Pacific Islander patients
Asian American and Pacific Islander patients have a longer time to melanoma treatment compared with white patients.